Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus MUPIROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus MUPIROCIN.
DIFICID vs MUPIROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
200 mg (tablet) orally twice daily for 10 days.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Category C
Category A/B
Antibiotic
Antibiotic